Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GB-7624

Other · developed by Generate Biomedicines

Phase 1 Most advanced trial
GENB Developer
1 Registered trials

What is GB-7624?

GB-7624 is an investigational drug studied in Atopic Dermatitis (AD).

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Generate Biomedicines (GENB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06920693 Phase 1 Atopic Dermatitis (AD) Active not recruiting GENB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis (AD)

More from Generate Biomedicines

Follow GENB, the company behind GB-7624

See GENB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GENB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.